Vutiglabridin

Vutiglabridin
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2H-pyrano[2,3-h]chromen-3-yl)-5-ethoxyphenol;
CAS Number	1800188-47-9;
PubChem CID	118204185;
UNII	7AWD9J49UP;
Chemical and physical data
Formula	C22H26O4
Molar mass	354.446 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC(=C(C=C1)C2CC3=C(C4=C(C=C3)OC(CC4)(C)C)OC2)O;
	InChI InChI=1S/C22H26O4/c1-4-24-16-6-7-17(19(23)12-16)15-11-14-5-8-20-18(21(14)25-13-15)9-10-22(2,3)26-20/h5-8,12,15,23H,4,9-11,13H2,1-3H3; Key:IUXJXQLTUMGHHL-UHFFFAOYSA-N;

Vutiglabridin (HSG4112) is an experimental anti-obesity drug that is a synthetic structural analog of glabridin.^[1]^[2]^[3]

References

↑ Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon (October 2023). "Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions". Experimental Gerontology. 181 112269. doi:10.1016/j.exger.2023.112269. PMID 37567452.
↑ Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung-Sang; Jang, In-Jin; Yoo, Sang-Ku; Kim, Youngah; Oh, Jaeseong (November 2022). "Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human study". Clinical and Translational Science. 15 (11): 2744–2757. doi:10.1111/cts.13401. ISSN 1752-8054. PMC 9652434. PMID 36176051.
↑ Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku (January 2021). "Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity". International Journal of Obesity. 45 (1): 130–142. doi:10.1038/s41366-020-00686-1. ISSN 1476-5497. PMC 7752758. PMID 32943760.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by adding missing information.